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indication continues to be stable or unstable ino­
tropic dependence due to severe left ventricu­
lar dysfunction in patients who have already 
been listed for or are considered to be listed for 
OHT.3,4 In the last decade, LVADs have become 
the predominant technology used in the man­
agement of this population, showing satisfacto­
ry outcomes in terms of significantly improved 
survival and quality of life. The total number of 
implantations worldwide has already exceed­
ed 17 000.5-7
INTROduCTION It is estimated that heart fail­
ure (HF) currently affects 26 million people, and 
its prevalence is expected to increase by 46% in 
2030.1,2 Orthotopic heart transplant (OHT) is 
considered the gold standard treatment for end­
­stage HF. However, owing to the shortage of do­
nors, new technologies such as ventricular as­
sist devices, predominantly left ventricular as­
sist devices (LVADs), have emerged as a poten­
tial therapeutic alternative. While indications for 
LVAD implantation constantly evolve, the main 
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AbsTRACT
INTROduCTION An increasing number of patients with end ‑stage heart failure, along with a shortage of 
heart donors, necessitates the use of mechanical circulatory support.
ObjECTIvEs This single ‑center retrospective study evaluated short‑ and long ‑term outcomes of 
continuous ‑flow left ventricular assist device (CF ‑LVAD) therapy in patients with end ‑stage heart failure.
PATIENTs ANd mEThOds We collected and assessed data of 79 patients (77 men, 2 women; mean age, 
50.3 years; mean INTERMACS profile, 3.1) implanted with a CF ‑LVAD between 2009 and 2017 (HeartMate 3 
in 19 patients [24%]; HeartMate 2 in 9 [11.4%]; and HeartWare in 51 [64.6%]).
REsuLTs The mean time on CF ‑LVAD support was 604 days (range, 1–1758 days). There were 2 device 
exchanges due to pump thrombosis and 1 explantation due to heart regeneration; 9 patients (11.4%) 
underwent heart transplant. Stroke (nondisabling, 48%) occurred in 27.8% of patients (ischemic in 9 
patients; hemorrhagic, in 14; both types, in 1) despite the standardized anticoagulation regimen. Major 
gastrointestinal bleeding and pump thrombosis were reported in 13 patients (16.5%), while 18 patients 
(22.8%) developed driveline infections (recurrent in 15 patients [19%]). Hemorrhagic stroke and bacteremia 
had a negative impact on survival. Hemorrhagic stroke was the main cause of death. Survival probability 
was 0.9 at 1 month and 0.81, 0.71, 0.61, and 0.53 at 1, 2, 3, and 4 years, respectively.
CONCLusIONs Although CF ‑LVAD support is associated with substantial adverse events, they do not 
significantly affect mortality (except hemorrhagic stroke and bacteremia). Novel devices seem to over‑
come these limitations, but larger studies are needed to support these findings.
POLISH ARCHIVES OF INTERNAL MEDICINE 2020; 130 (7-8)590
1 (1.3%), with an Impella device; and 1 (1.3%), 
with a CentriMag device.
All patients were considered as transplant can­
didates at the time of LVAD implantation. In 19 
patients (24%), the HeartMate 3 (HM3) pump 
was implanted; in 9 patients (11.4%), HeartMate 2 
(HM2); and in 51 patients (64.6%), HeartWare 
(HVAD). All patients implanted with HVAD and 
HM2 had full sternotomy performed at CF ­LVAD 
implantation (66 [83.6%]). In 11 patients (13.9%) 
with HM3, a less invasive technique (minister­
notomy and lateral minithoracotomy) was used. 
In 9 patients (11.4%), the HM3 implantation was 
accompanied with left atrial appendage closure 
(AtriClip PRO, AtriCure, Mason, Ohio, United 
States).
All patients were initially treated according to 
a standardized anticoagulation regimen, which 
consisted of unfractionated or low ­molecular­
­weight heparin early in the postoperative pe­
riod, followed by warfarin and an international 
normalized ratio (INR) target between 2 and 3. 
During follow ­up, plasma INR levels were mea­
sured every 2 to 3 months at every ambulato­
ry visit or at least once during hospitalization in 
our institution.
An antiplatelet drug such as aspirin or clop­
idogrel (the latter used only in cases of aspirin 
resistance or other indications for this drug) 
at a dose of 75 mg/d was introduced on postop­
erative day 1 and uptitrated according to aggre­
gation tests in cases of diminished sensitivity to 
a currently used drug.
Continuous warfarin therapy during LVAD 
support was administered to 73 patients, while 
in 6 patients, it was discontinued or never in­
troduced due to adverse events (AEs). Aspirin 
was given to 26 patients (mean [SD] dose, 113 
[53] mg) and clopidogrel, to 44 (mean [SD] dose, 
107 [61] mg). In 1 patient, both medications were 
administered (both at a dose of 75 mg and in com­
bination with warfarin) due to thromboembolic 
events during LVAD support. In 8 patients, an­
tiplatelet therapy was discontinued, while in 19 
patients, the typical protocol including a target 
INR of 2 to 3 was changed due to severe recurrent 
bleedings or thromboembolic events.
All patients were either discharged home or re­
ferred to a cardiac rehabilitation center.
Adverse events Adverse events such as stroke, 
pump thrombosis (PT), driveline infections (DLI), 
and major gastrointestinal (GI) bleeding were 
defined according to the INTERMACS Adverse 
Events Definitions (December 6, 2015). Short­
­term TCS such as intra ­aortic balloon pump, 
ECMO, and mid ­term circulatory support devic­
es were defined as TCS modifiers of the INTER­
MACS profile according to the INTERMACS Ad­
verse Events Definitions (December 6, 2015) and 
the study by Cowger et al.8,9
statistical analysis Baseline characteristics 
were presented as numbers and percentages for 
The objective of this study was to assess the out­
comes of continuous ­flow LVAD (CF ­LVAD) ther­
apy in patients with end ­stage HF treated in a sin­
gle institution, including issues relating to early 
implantations and the learning curve.
PATIENTs ANd mEThOds The study was de­
signed as a retrospective single ­center regis­
try, with data collected prospectively (part of 
the EUROMACS registry [European Registry for 
Patients with Mechanical Circulatory Support]). 
The study was approved by the appropriate insti­
tutional review board.
Baseline demographic, clinical, and laborato­
ry characteristics as well as perioperative data of 
79 patients implanted with a CF ­LVAD from De­
cember 2009 to December 2017 (follow ­up un­
til March 2018) were collected and assessed. Pa­
tients were followed until death, pump explan­
tation, end of follow­up, or OHT. There were 77 
men (97.5%) and 2 women (2.5%) at a mean (SD) 
age of 50.3 (11.3) years (range, 16.7–72.4 years) 
and with a mean (SD) body mass index of 25.5 
(5.1) kg/m2 (range, 13.8–45.2 kg/m2). Two of 
the 79 patients were implanted outside our in­
stitution and were referred to our center within 
the first 3 months after implantation. The clin­
ical characteristics of the study group are pre­
sented in TAbLE 1.
Ischemic cardiomyopathy was the major cause 
of HF (36 [45.6%] of patients), followed by di­
lated cardiomyopathy (27 [34.2%] of patients). 
The duration of HF varied from a few weeks up 
to over 10 years. The distribution of patients ac­
cording to the INTERMACS profile (The Inter­
agency Registry of Mechanically Assisted Circu­
latory Support) at the time of CF ­LVAD implan­
tation and echocardiographic evaluation before 
LVAD implantation are shown in TAbLEs 2 and 3, 
respectively.
At the time of LVAD implantation, 57 patients 
(72.1%) were on inotropic support, while 34 pa­
tients (43%) were bridged with temporary cir­
culatory support (TCS): 30 (38%) with an intra­
­aortic balloon pump; 2 (2.5%), with venoarterial 
extracorporeal membrane oxygenation (ECMO); 
whAT’s NEw?
The number of patients with heart failure, including the end ‑stage form of this 
disease, is constantly increasing. Due to a worldwide shortage of heart donors, 
new technologies have come into play, such as mechanical circulatory support. 
In the last decade, continuous ‑flow left ventricular assist devices (CF ‑LVADs) 
have become the predominant technology used in this population of severely 
ill patients. This type of therapy enables survival to heart transplant or heart 
regeneration and improves the quality of life, but it is not free from limita‑
tions, mainly device ‑related adverse events. The analysis of the frequency and 
causes of adverse events during CF ‑LVAD support could facilitate the search 
for preventive strategies. Moreover, the knowledge on the timing of these 
events as well as their impact on survival could help choose the optimal time 
frame for heart transplant in this population of patients.
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An actuarial survival analysis was performed us­
ing the Kaplan–Meier method. Log ­rank tests 
were used to compare different groups. In the uni­
variable analysis, all reported values were 1 ­tailed, 
whereas in the Cox multivariable analysis, they 
were 2 ­tailed. A P value less than 0.05 was con­
sidered significant. Data were analyzed with 
the Stata 15 software (StataCorp LLC, College 
Station, Texas, United States).
REsuLTs All implantations were performed 
on cardiopulmonary bypass. The mean time of 
surgery was 6 hours and 14 minutes (median, 5 
hours and 40 minutes) with a mean cardiopulmo­
nary bypass at 83 minutes (median, 69 minutes; 
range, 12–494 minutes). In 70 patients (88.6%), 
nitric oxide inhalation was used postoperatively 
at a mean time of 15.9 hours (median, 16 hours; 
range, 1–131 hours). The mean time of postoper­
ative ventilation was 26 hours and 44 minutes 
(median, 18 hours and 25 minutes). Thirteen pa­
tients (16.4%) required renal replacement therapy 
at a mean time of 8.3 days (median, 7 days; range, 
2–17 days), while 3 patients required intraopera­
tive or postimplantation ECMO, including 1 pa­
tient with severe right ventricular failure (RVF).
The mean stay at the intensive care unit af­
ter implantation was 14 days (median, 7 days; 
range, 1–128 days). The mean length of hospital 
stay was 61 days (median, 53 days; range, 4–228 
days). The mean time from implantation to dis­
charge or in ­hospital death was 36 days (median, 
29 days; range, 1–125 days).
The overall reoperation rate was 30.4% (24 pa­
tients), and the predominant cause was bleeding 
(23 [29.1%]). One patient underwent reposition 
of an inflow cannula after 2 days because of in­
appropriate pump placement.
Early postoperative outcomes There were no in­
traprocedural deaths. One patient experienced 
nondisabling stroke. The 30 ­day mortality rate 
was 10%, and the 30 ­day stroke rate, 7.6% (3 pa­
tients, hemorrhagic stroke [HS]; 3 patients, isch­
emic stroke [IS]; including 1 patient who had HS 
and subsequently IS).
Long -term outcomes on left ventricular assist de-
vice support The mean time on LVAD support 
was 604 days (median, 426 days; range, 1–1758 
days). The mean time to death was 399 days (me­
dian, 245 days; range, 1–1471 days). A total of 
130.6 patient ­years were analyzed (96.1, 22.4, 
and 12.1 for HVAD, HM2, and HM3, respective­
ly). There were 2 device exchanges (one due to PT 
and the other due to pump ­associated infection) 
and 1 pump explantation due to heart regenera­
tion. Nine patients (11.4%) underwent OHT af­
ter a mean time of 656 days (median, 608 days; 
range, 323–1058 days).
The probability of 1­, 3­, and 6 ­month survival 
according to the Kaplan–Meier analysis was 0.9, 
0.89, and 0.87, respectively, while the probability 
of 1 ­year survival was 0.81; 2 ­year, 0.71; 3 ­year, 
categorical variables, and as mean (SD) and medi­
an for continuous variables. In a univariable anal­
ysis, categorical variables were compared using 
the 1 ­sided exact Fisher test. An additional Cox 
multivariable analysis was performed to confirm 
predictors of mortality among LVAD ­related AEs. 
TAbLE 1 Baseline characteristics of the study patients (n = 79)
Characteristic Patients, n (%)
Diabetes 28 (35.4)
Arterial hypertension 28 (35.4)
Chronic kidney disease stage 3 or higher 34 (43)
Chronic obstructive pulmonary disease 3 (3.8)
Atrial fibrillation or flutter 45 (57)
Carotid artery disease 35 (44.3)
Sustained ventricular arrhythmia or sudden cardiac arrest 37 (46.8)
Prior myocardial infarction 33 (41.8)
Prior ischemic stroke 11 (13.9)
Prior transient ischemic attack 5 (6.3)
History of cardiac surgical intervention 13 (16.4)
History of percutaneous coronary intervention 29 (36.7)
History of percutaneous mitral valve intervention 2 (2.5)
TAbLE 2 Distribution of patients (n = 79) according to the INTERMACS profile at the 
time of continuous ‑flow left ventricular assist device implantation
INTERMACS patient profile Patients, n (%)
Level 1: critical cardiogenic shock 10 (12.7)
Level 2: progressive decline 23 (29.1)
Level 3: stable but inotrope‑dependent 24 (30.4)
Level 4: resting symptoms 8 (10.1)
Level 5: exertion intolerant 6 (7.6)
Level 6: exertion limited 2 (2.5)
Level 7: advanced NYHA class 3 6 (7.6)
Abbreviations: NYHA, New York Heart Association
TAbLE 3 Echocardiographic measurements before continuous ‑flow left ventricular 
assist device implantation
Parameter Value
LV end ‑diastolic diameter, mm 75 (10), 50–110
LV end ‑systolic diameter, mm 67 (11), 39–98
LV end ‑diastolic volume, ml 308 (112), 152–670
LV end ‑systolic volume, ml 256 (98), 100–576
LV ejection fraction, % 17 (4), 8–34
RV dimension (M mode), mm 35 (7), 22–53
TAPSE, mm 15 (3), 8–23
RV systolic pressure, mm Hg 47 (14), 17–80
Aortic regurgitation gradea, median (IQR), range 0 (1), 0–3
Mitral regurgitation gradea, median (IQR), range 3 (1), 0–4
Tricuspid regurgitation gradea, median (IQR), range 2.5 (1), 0–4
Data are presented as mean (SD), minimum–maximum unless otherwise indicated.
a Valve regurgitation grade: 1, trace; 2, mild; 3, moderate; 4, severe
Abbreviations: IQR, interquartile range; LV, left ventricular; RV, right ventricular; 
TAPSE, tricuspid annular plane systolic excursion
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of oral or intravenous antibiotics because of DLI 
was necessary 1 to 7 times (mean, 3.1) per pa­
tient after a mean time of 14 months (median, 12 
months; range, 4–48 months). A surgical inter­
vention was necessary in 8 patients (44.4%) after 
a mean time of 19 months (median, 19 months; 
range, 12–25 months) at a mean rate of 2.6 times 
(median, 2 times; range, 1–5 times).
There were no pump pocket infections. Bac­
teremia after CF ­LVAD implantation occurred 
in 22 patients (27.8%), after a mean time of 301 
days (median, 119 days; range, 0–1212 days). In 
5 patients with DLI, bloodstream infection with 
the same pathogen occurred after a mean of 738 
days (median, 742 days; range, 409–1212 days).
major bleeding In our study, major GI bleed­
ing occurred in 13 patients (16.5%), including 
4 patients with recurrent bleeding. There were 
21 major nasal bleedings (NB), which occurred 
in 12 patients (15.2%). Major bleedings appeared 
relatively early after implantation, with a mean 
time to first event of 127 days for NB (median, 
24 days; range, 3–645 days) and 270 days for GI 
bleeding (median, 132 days; range, 19–1163 days).
Right ventricular failure In our study, 40.2% of 
patients required prolonged inotropic support 
over 7 days and 15.6%—over 14 days from im­
plantation, which might indicate RVF. Severe RVF 
requiring temporary right ventricular support 
(ECMO used) was found in 1 patient.
mortality data The overall mortality rate during 
LVAD support was 31.6% (25 patients). The main 
cause of death was HS (9 patients [11.4%]). Four 
patients died of multiorgan failure; 3, of severe 
pneumonia; 2, of PT; and 2, of IS. Another causes 
included pulmonary embolism (1 patient), intra­
cerebral posttraumatic bleeding (1 patient), ile­
us (1 patient), and perioperative bleeding (1 pa­
tient). Data on the cause of death were unavail­
able in 1 patient.
Events per patient -year Events per patient ­year 
were calculated overall and for individual devices. 
Although it was not the main focus of our study, 
a preliminary analysis of events per patient ­year 
revealed better outcomes for HM3 patients com­
pared with those for HVAD and HM2 patients, 
with an obvious limitation of a shorter support 
time. In the HM3 group, no HS, PT, or GI bleed­
ing were observed (TAbLE 4).
International normalized ratio analysis Due to 
a relatively high rate of stroke in our study, we 
analyzed all in ­hospital INRs and those mea­
sured during ambulatory visits. There were 3152 
INR measurements performed for 79 patients. 
The mean (SD) INR value was 2.15 (0.8) and 
the median INR value was 2.1 (range, 0.9–10.1). 
The percentage of INR of 2 to 3 was 0.49% for 
all measurements; INR below 2, 0.41%; and INR 
above 3, 0.1%. The percentages of INR of 2 to 3, 
0.61; and 4 ­year, 0.53 (FIGuRE 1). Six patients re­
mained on support longer than 4 years. 
strokes and transient ischemic attack Stroke was 
noted in 22 patients (27.8%): IS in 9 patients 
(11.4%) and HS in 14 patients (17.7%); 1 pa­
tient had both. Disabling stroke occurred in 12 
patients (15.2%) and transient ischemic attack 
(TIA), in 7 patients (8.9%) after a mean time of 
455 days (median, 302 days; range, 72–1151 days). 
The mean time to IS was 401 days (median, 207 
days; range, 0–1609 days) and to HS, 490 days 
(median, 373 days; range, 1–1465 days).
Pump thrombosis Suspected or confirmed PT was 
found in 13 patients (16.5%). All patients received 
medical treatment and 1 patient was treated with 
successful pump exchange.10 Pump thrombosis 
occurred after a mean time of 608 days (medi­
an, 563 days; range, 15–1351 days).
Left ventricular assist device–associated infections 
In the postoperative period, 3 patients (3.8%) 
developed wound infection at a mean time of 46 
days (median, 41 days; range, 19–79 days) and 
1 patient developed bacterial peritonitis after 45 
days from LVAD implantation. Pneumonia (con­
firmed by chest radiography or microbiological 
tests) was reported in 17 patients (21.5%); 20 pa­
tients (25.3%) developed other kind of infection; 
and in 14 patients (17.7%), fever of unknown or­
igin was observed (all microbiological tests were 
negative). One patient (1.3%) had fungemia and 
8 patients (10.1%) had bacteremia after a mean 
time of 19.4 days (median, 17 days; range, 0–42 
days) from implantation.
Driveline infections were present in 18 patients 
(22.8%), of whom 15 (19%) developed a chronic 
condition. The first symptoms of DLI were ob­
served after a mean time of 351 days (median, 
351 days; range, 21–960 days). The introduction 
TAbLE 4 Distribution of adverse events for different types of pumps
Adverse event HVAD device 
(n = 51), 
PY = 96.1
HM2 device 
(n = 9), 
PY = 22.4
HM3 device 
(n = 19), 
PY = 12.1
Total 
(n = 79), 
PY = 130.6
Hemorrhagic stroke 0.125 (23.5) 0.089 (22.2) 0 0.107 (17.7)
Ischemic stroke 0.073 (13.7) 0.045 (11.1) 0.083 (5.3) 0.069 (11.4)
Pump thrombosis 0.094 (17.6) 0.179 (44.4) 0 0.099 (16.5)
TIA 0.073 (13.7) 0 0 0.054 (8.9)
Major gastrointestinal 
bleeding
0.104 (19.6) 0.134 (0.33) 0 0.099 (16.5)
Major nasal bleeding 0.094 (17.6) 0 0.248 (15.8) 0.092 (15.2)
Driveline infection 0.125 (23.5) 0.223 (55.5) 0.083 (5.3) 0.138 (22.8)
Bacteremia 0.156 (29.4) 0.089 (22.2) 0.413 (26.3) 0.168 (27.8)
Bacteremia + driveline 
infection
0.042 (7.8) 0.045 (11.1) 0 0.038 (6.3)
Death 0.198 (37.2) 0.134 (33.3) 0.248 (15.8) 0.191 (31.6)
Data are presented as the number (percentage) of events per patient ‑year. 
Abbreviations: HM2, HeartMate 2; HM3, HeartMate 3; HVAD, HeartWare; PY, patient‑
‑year; TIA, transient ischemic attack
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use of inotropes for RHF (P = 0.046). The lack of 
treatment with β ­blockers, angiotensin II recep­
tor antagonists, sildenafil, and protein pump in­
hibitors also correlated with mortality (P ≤0.001, 
0.002, 0.01, and 0.03 respectively). Mortality was 
associated with HS (P ≤0.001) and bacteremia 
(P = 0.01), while no associations were observed 
for IS (P = 0.59), PT (P = 0.35), TIA (P = 0.06), 
GI bleeding (P = 0.39), NB (P = 0.43), and DLI 
(P = 0.46). When all analyzed AEs except HS and 
bacteremia were included in the analysis, no im­
pact on survival was observed (P = 0.09). Surviv­
al curves depending on the incidence of a particu­
lar AE were compared using log ­rank tests, which 
also showed poorer survival only for patients with 
HS (P = 0.001) or bacteremia (P = 0.007) (FIGuREs 2 
and 3). The Cox multivariable analysis also con­
firmed HS (P = 0.027; hazard ratio [HR], 2.7) and 
bacteremia (P = 0.027; HR, 2.8) to be independent 
below 2, and above 3 were 0.54%, 0.34%, and 
0.12%, respectively, for PT; 0.56%, 0.33%, and 
0.11%, respectively, for IS; 0.56%, 0.35%, and 
0.09%, respectively, for TIA; 0.47%, 0.4%, and 
0.13%, respectively, for HS; 0.46%, 0.45%, and 
0.09%, respectively, for GI bleeding; 0.5%, 0.43%, 
and 0.08%, respectively, for NB; as well as 0.44%, 
0.41%, and 0.14%, respectively, for a group of de­
ceased patients.
mortality predictors in patients on left ventricular as-
sist device support The univariable analysis re­
vealed the following preimplantation conditions 
to be significant predictors of death: paroxys­
mal atrial fibrillation (P = 0.047), diabetes (0.03), 
and carotid artery disease (0.02). When postim­
plantation factors were considered, death corre­
lated with bacteremia (P = 0.01), renal replace­
ment therapy (P = 0.002), and the postoperative 
FIGuRE 1  
Kaplan–Meier survival 
curve for continuous ‑flow 
left ventricular assist 
device (CF ‑LVAD) therapy
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FIGuRE 2 Survival of 
patients on continuous‑
‑flow left ventricular 
assist device (CF ‑LVAD) 
support depending on 
the incidence of 
hemorrhagic stroke (HS)
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a continuous improvement of technology, mor­
bidity and mortality rates are significant, espe­
cially when considering older generations of ven­
tricular assist devices. The knowledge of surviv­
al data, predictors of mortality, and AEs during 
LVAD support facilitates the search for preven­
tive measures and the choice of the best strate­
gy for individual patients.5
Our study demonstrated survival rates (early 
and late) that ranged in between those reported in 
the EUROMACS and INTERMACS registries (30 
days, 88% and 95%, respectively; 1 year, 69% and 
81%, respectively; 2 years, 55% and 70%, respec­
tively; and 3 years, 44% and 59%, respectively).5,11 
Our results are also in agreement with the recent­
ly published IMACS registry (ISHLT Mechanical­
ly Assisted Circulatory Support), including 13 000 
patients implanted with CF ­LVAD, which report­
ed the 1­ and 6 ­month survival rates of 95% and 
86%, respectively. It is also in line with a study by 
Tsiouris et al,12,13 including 200 patients (mean 
duration of LVAD support, 581 days), who re­
ported the 30 ­day, 6 ­month, as well as 1­, 2­, 3­, 
and 4 ­year survival rates of 94%, 96%, 78%, 71%, 
predictors of mortality among LVAD ­related AEs. 
The remaining AEs did not show any significant 
impact on mortality (for PT, P = 0.083 [HR, 0.33]; 
for IS, P = 0.62 [HR, 1.4]; for GI bleeding, P = 0.66 
[HR, 0.79]; for NB, P = 0.6 [HR, 0.72]; and for 
DLI, P = 0.06 [HR, 0.38]).
The type of CF ­LVAD, the INTERMACS pro­
file 1–3 versus 4–7, age group, and HF before im­
plantation were also analyzed, but no differenc­
es in survival were observed (P = 0.84, P = 0.73, 
P = 0.38, and P = 0.25, respectively).
The major outcomes of CF ­LVAD therapy such 
as OHT, pump explantation due to heart regen­
eration, death, or staying alive on LVAD support 
were depicted in FIGuRE 4 as competing outcomes 
over time.
dIsCussION Our study investigated short­ and 
long ­term outcomes in heart transplant candi­
dates bridged with CF ­LVAD support, with a spe­
cial focus on the timing of LVAD ­related AEs and 
associated mortality risk. The number of CF ­LVAD 
implantations gradually increases worldwide 
owing to good survival rates. However, despite 
FIGuRE 3 Survival of 
patients on continuous‑
‑flow left ventricular 
assist device (CF ‑LVAD) 
support depending on 
the incidence of 
bacteremia




















19 19 16 13 8 3 0Bacteremia present
52 50 43 33 22 12 6Bacteremia absent
Patients at risk
FIGuRE 4 Competing 
outcomes of patients on 
continuous ‑flow left 
ventricular assist device 
(CF ‑LVAD) support 
Abbreviations: 













0 12 24 36 48 60
 Time on CF-LVAD support, mo






ORIGINAL ARTICLE Outcomes of left ventricular assist device therapy 595
Kumar et al20 identified ischemic etiology as 
an independent predictor of mortality in patients 
with CF ­LVAD. Our study found that only some 
of the factors discussed above had an impact on 
mortality.
In the latest IMACS report, infection and bleed­
ing each affected over one ­third of patients. In 
our study, GI bleeding and NB occurred at a sim­
ilar rate, but LVAD ­related infections affected 
more patients.12
According to Patel et al,21 CF ­LVAD is the “sec­
ond hit” causing bleedings in predisposed pa­
tients, such as those with severe HF and acquired 
von Willebrand syndrome. In their study, epistax­
is was strongly associated with GI bleeding. Such 
a relation was not investigated in our group, but 
it would be interesting to identify predictors and 
possible relationships of these types of bleed­
ing in future studies. Tsiouris et al13 reported 
that the most frequent AE was GI bleeding (21%), 
followed by RVF (19%) and stroke (15%). In our 
study, RVF was less frequent probably due to 
a careful selection of patients before LVAD im­
plantation. In another study, the incidence of GI 
bleeding was 23.9% and it was correlated with 
chronic kidney disease.22 A lower incidence of GI 
bleeding in our study is probably due to the fact 
that we used extensive diagnostic measures be­
fore implantation. Endoscopy of at least the up­
per GI tract was performed in all possible candi­
dates, and proton pump inhibitors were used in 
most patients after implantation.
The PREVENT multi center study23 (Prevention 
of HeartMate II Pump Thrombosis Through Clini­
cal Management) reported a PT rate of up to 8.9% 
in the first 6 months of follow ­up, although full 
adherence to optimal implantation techniques, 
heparin bridging, and pump speed recommen­
dations resulted in a significantly lower risk of 
PT (1.9%). In that study, no significant difference 
in survival depending on PT was found, which is 
in line with our study. In a meta ­analysis includ­
ing over 28 000 patients, PT occurred in 10.6%.24 
Our data show higher PT rates, which is proba­
bly related to a heterogeneity of pump types and 
a relatively long LVAD support. The number of PT 
events could probably be reduced with routine di­
agnostic tests prior to surgery that identify lu­
pus anticoagulant, heparin ­induced thrombocy­
topenia antibodies, factor V Leiden, protein C or 
antithrombin III deficiency, as well as antiphos­
pholipid syndrome. However, some of the above 
tests were routinely introduced in our institution 
in 2017, so they were not performed in patients 
implanted earlier.25
There are few studies comparing survival and 
AEs in different types of CF ­LVADs. As the ma­
jority of patients in our institution were implant­
ed with HVAD, we focused on this analysis, al­
though a preliminary assessment of the events 
per patient ­year for various CF ­LVADs showed 
the best results for HM3. Stulak et al26 compared 
outcomes between HM2 and HVAD and reported 
a trend for a higher incidence of DLI in patients 
62%, and 45%, respectively (as compared with 
90%, 87%, 81%, 71%, 61%, and 53%, respective­
ly, in our study).
In the study by Tsiouris et al,13 the mean length 
of hospital stay was 21 days and 11 days in the in­
tensive care unit, which is comparable with the re­
sults reported by Starling et al14 but slightly short­
er than in our study group. The discrepancy prob­
ably results from the severe condition of patients 
before implantation and the lack of a rehabilita­
tion unit in our institution at the time the major­
ity of patients were implanted. Therefore, the re­
habilitation period in our study had been includ­
ed in the implantation hospital stay.
Multiorgan failure, RVF, and stroke posed 
the  greatest risk of death according to the 
INTERMACS data, while the EUROMACS reg­
istries reported multiorgan failure and infec­
tions.5,11,15,16 Stroke remained the leading cause 
of death in our cohort (13.9%). On the other 
hand, multiorgan failure was often secondary to 
cerebral insult and resulted in patient death in 
5.1% of cases, which is much lower when com­
pared with the above registries.
A recent stroke analysis of the INTERMACS 
database revealed that prognosis for HS was sig­
nificantly worse than for IS and that the first 
HS posed a higher risk of another stroke.17 In 
some smaller studies, survival rates after stroke 
were higher, although long ­term mortality risk 
in patients with stroke was twice as high as that 
in stroke ­free individuals.18 Our results showed 
high mortality rates for HS, which may be re­
lated to a relatively long time of LVAD sup­
port, more comorbidities, and a more advanced 
stage of HF at LVAD implantation, as expressed 
by a higher rate of patients with INTERMACS 
profile 1 in our population. Relatively low in­
­hospital and ambulatory plasma INR levels 
were probably not associated with a higher rate 
of HS. However, further studies are needed to 
explore this issue.
Our cohort also represents early experience 
in ventricular assist device placement, as indi­
cated by 12.7% of patients undergoing implan­
tation due to cardiogenic shock (INTERMACS 1), 
which is probably associated with a more limit­
ed access to short­ or mid ­term left ventricular 
support devices in earlier years. In the sixth IN­
TERMACS report (9112 patients), early mortali­
ty was higher in patients with INTERMACS pro­
files 1–2 as compared with those with profiles 
3–4, with infection and multiorgan failure found 
to be the major causes of death.15,19 Yet, in our 
study, no significant differences were observed 
between INTERMACS profiles 1–3 and 4 ­6 re­
garding early and late outcomes. However, we 
did not assess every INTERMACS profile because 
profile 2 or 3 was found in almost 60% of our pa­
tients and other groups were less numerous. In 
future studies, when our LVAD population be­
comes larger, we are planning to assess survival 
according to the INTERMACS profile, especially 
INTERMACS 1.
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power. Moreover, some perioperative data were 
not available, mostly for patients who underwent 
implantation outside our institution. In addition, 
the INR analysis included early postoperative 
measurements as well as those taken during tem­
porary warfarin withdrawal for various reasons. 
Ambulatory self ­measured INR levels were not 
available and were not included in this analysis.
Conclusions In patients with end ­stage HF, 
CF ­LVAD support improves survival. Despite 
the numerous benefits of CF ­LVAD, the frequen­
cy of AEs remains substantial, although most of 
them occur after 1 year of LVAD support. Adverse 
events do not have a significant impact on mor­
tality, except for HS and bacteremia. Preimplan­
tation patient selection and treatment of AEs 
should focus on reducing the incidence and bur­
den of AEs for further improvement of surviv­
al. Novel devices seem to overcome these short­
comings, but larger studies are needed to sup­
port these findings.
CORRECTIONs
This article was corrected on October 29, 2020. The list of corrections is 
available at www.mp.pl/paim.
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